OptiCell Solutions enters into new collaboration

— PRESS RELEASE —
OptiCell Solutions initiates collaboration with NextCell Pharma – strengthening operations in cell and gene therapies
Huddinge, Sweden 02-DEC-2025

OptiCell Solutions AB (“OptiCell”) is pleased to announce a strategically important step in our journey to improve patient care: the new collaboration with NextCell Pharma AB (“NextCell”).

Together, we are taking on a central mission in advanced cell therapy research: ensuring rapid access to high-quality apheresis-based cell collections and adhering to regulatory guidelines for cell handling. Both organizations are based at Novum in Huddinge and share a common ambition to strengthen the national infrastructure required to drive groundbreaking developments in cell and gene therapies.

OptiCell has signed a collaboration agreement with NextCell regarding the handling, freezing, storage, and transport of cell products for research and development. Through this collection, OptiCell expands its portfolio of high-quality cell products with the support of NextCell´s existing infrastructure and expertise in advanced cell handling.

“The collaboration with NextCell Pharma enables us to achieve more advanced cell management that increases the flexibility to deliver high-quality cell products for cell and gene therapies,” says Jarmo Henriksson, CEO of OptiCell Solutions.

According to the agreement, OptiCell Solutions is responsible for donor and customer relations, including planning and management of the apheresis operations at its own clinic at Novum Labs in Huddinge. NextCell is responsible for cell handling, freezing, storage, and logistics. The companies take together another step toward establishing themselves as broader players in the cell therapy value chain, from cell donor to finished product.

“The collaboration with OptiCell Solutions fits perfectly into our daily operations. We will use existing staff and laboratory equipment and will also purchase services from our subsidiaries, QVance and Cellaviva,” says Mathias Svahn, CEO of NextCell Pharma.

About NextCell Pharma AB
NextCell Pharma AB is a clinical-stage cell therapy company developing ProTrans™, an allogeneic mesenchymal stromal cell therapy for autoimmune and inflammatory diseases, with type 1 diabetes as the lead indication. In addition to ProTrans, NextCell owns two subsidiaries: Cellaviva AB, Scandinavia’s largest private stem cell bank, and QVance AB, offering quality control analytics for developers of advanced therapies. For more information, visit www.nextcellpharma.com
— END PRESS RELEASE —

PRESS RELEASE 02DEC2025

For more information, please contact
General Manager, Jarmo Henriksson, +46 (0) 73 699 48 37, jarmo.henriksson@opticellsolutions.com
Chairman of the board, Peter Rybäck, +46 (0) 73 849 07 96, peter.ryback@opticellsolutions.com

About OptiCell Solutions
Founded in 2024, OptiCell Solutions AB specializing in the field of apheresis collection for Cell and Gene Therapy (CGT). By using our advanced apheresis technology, we can collect large quantities of specific donor cells, significantly advancing applications within in the CGT. Furthermore, our extensive experience and know-how in apheresis enable us to offer specialized therapeutic apheresis services to the healthcare sector.
Located near the Karolinska University Hospital in Huddinge we aim to bridge the gap in resources by offering innovative solutions that enhance the availability of essential cells for cutting-edge research and life-saving therapies. With our deep expertise in apheresis technology and a strong commitment to ethical research practices, we are dedicated to improving patient outcomes and supporting the development of next-generation therapies for cancer care, autoimmune diseases, and other severe medical conditions.
At OptiCell Solutions, we strive to be at the forefront of medical innovation, providing the tools and services necessary to accelerate the transition to more effective and patient-centred care. For more information visit our website, www.opticellsolutions.com and follow us at LinkedIn.